Publications

2017

Mixed aryl phosphonate prodrugs of a butyrophilin ligand. B. J. Foust, M. M. Poe, N. A. Lentini, C. H. Hsiao, A. J. Wiemer, D. F. Wiemer. ACS Med Chem Lett.

Novel tropolones induce the unfolded protein response pathway and apoptosis in multiple myeloma cells. S. L. Haney, C. Allen, M. L. Varney, K. M. Dykstra, E. R. Falcone, S. H. Colligan, Q. Hu, A. M. Aldridge, D. L. Wright, A. J. Wiemer, S. A. Holstein. Oncotarget.

The butyrophilin 3A1 intracellular domain undergoes a conformational change involving the juxtamembrane region. K. Nguyen, J. Li, R. Puthenveetil, X. Lin, M. M. Poe, C. H. Hsiao, O. Vinogradova, and A. J. Wiemer. FASEB Journal. PubMed

Geranylgeranyl diphosphate synthase inhibition induces apoptosis that is dependent upon GGPP depletion, ERK phosphorylation and caspase activation. S. S. Agabiti, J. Li, A. J. Wiemer. Cell Death Dis. 8(3):e2678. 2017. PubMed

Phosphinophosphonates and their tris-pivaloyloxymethyl prodrugs reveal a negatively cooperative butyrophilin activation mechanism. R. R. Shippy, X. Lin, S. S. Agabiti, J. Li, B. M. Zangari, B. J. Foust, M. M. Poe, C. H. Hsiao, O. Vinogradova, D. F. Wiemer, and A. J. Wiemer. J Med Chem. 2017. PubMed

2016

Novel α-substituted tropolones promote potent and selective caspase-dependent leukemia cell apoptosis. J. Li, E. R. Falcone, S. A. Holstein, A. C. Anderson, D. L. Wright, A. J. Wiemer. Pharmacol Res. 113:438-448. 2016. PubMed

Synthesis and biological evaluation of santacruzamate A analogues for anti-proliferative and immunomodulatory activity. S. M. Gromek, J. A. deMayo, A. T. Maxwell, A. M. West, C. M. Pavlik, Z. Zhao, J. Li, A. J. Wiemer, A. Zweifach, M. J. Balunas. Bioorg Med Chem. 2016. PubMed

Molecular mechanisms linking geranylgeranyl diphosphate synthase to cell survival and proliferation. Agabiti SS, Liang Y, Wiemer AJ. Mol Membr Biol. 2016 Aug 18:1-11. PubMed

HMBPP analog prodrugs bypass energy-dependent uptake to promote efficient BTN3A1-mediated malignant cell lysis by Vγ9Vδ2 T lymphocyte effectors. Kilcollins AM, Li J, Hsiao CH, Wiemer AJ. J Immunol. PubMed

Evaluation of a 7-methoxycoumarin-3-carboxylic acid ester derivative as a fluorescent, cell-cleavable, phosphonate protecting group. Wiemer AJ, Shippy RR, Kilcollins AM, Li J, Hsiao CH, Barney RJ, Geng ML, Wiemer DF. Chembiochem. 2016; Jan 1;17(1):52-5. PubMed

2015

Prodrugs of phosphonates and phosphates: crossing the membrane barrier. Wiemer AJ and Wiemer DF. Topics in Current Chemistry. 2015 360:115-60. PubMed

2014

Synthesis of a phosphoantigen prodrug that potently activates Vγ9Vδ2 T-lymphocytes. Hsiao CH, Lin X, Barney RJ, Shippy RR, Li J, Vinogradova O, Wiemer DF, Wiemer AJ. Chem Biol. 2014 Aug 14;21(8):945-54. PubMed

Opportunities and challenges in development of phosphoantigens as Vγ9Vδ2 T cell agonists. Wiemer DF, Wiemer AJ. Biochem Pharmacol. 2014 Jun 1;89(3):301-12. PubMed

Cyclopropene cycloadditions with annulated furans: total synthesis of (+)- and (-)-frondosin B and (+)-frondosin a. Oblak EZ, Vanheyst MD, Li J, Wiemer AJ, Wright DL. J Am Chem Soc. 2014 Mar 19;136(11):4309-15. PubMed

2013

The focal adhesion kinase inhibitor PF-562,271 impairs primary CD4+ T cell activation.Wiemer AJ, Wernimont SA, Cung TD, Bennin DA, Beggs HE, Huttenlocher A. Biochem Pharmacol. 2013 Sep 15;86(6):770-81. PubMed

2012

Live imaging of LFA-1-dependent T-cell motility and stop signals. Wiemer AJ, Wernimont S, Huttenlocher A. Methods Mol Biol. 2012;757:191-204. PubMed

2011

Contact-dependent T cell activation and T cell stopping require talin1. Wernimont SA, Wiemer AJ, Bennin DA, Monkley SJ, Ludwig T, Critchley DR, Huttenlocher A. J Immunol. 2011 Dec 15;187(12):6256-67. PubMed

Geranylgeranyl diphosphate synthase: an emerging therapeutic target. Wiemer AJ, Wiemer DF, Hohl RJ. Clin Pharmacol Ther. 2011 Dec;90(6):804-12. PubMed

A live imaging cell motility screen identifies prostaglandin E2 as a T cell stop signal antagonist. Wiemer AJ, Hegde S, Gumperz JE, Huttenlocher A. J Immunol. 2011 Oct 1;187(7):3663-70. PubMed

2010

Isoprenoid metabolism as a therapeutic target in gram-negative pathogens. Wiemer AJ, Hsiao CH, Wiemer DF.Curr Top Med Chem. 2010;10(18):1858-71. PubMed

Calpain inhibition impairs TNF-alpha-mediated neutrophil adhesion, arrest and oxidative burst. Wiemer AJ, Lokuta MA, Surfus JC, Wernimont SA, Huttenlocher A. Mol Immunol. 2010 Jan;47(4):894-902. PubMed

2009

The intermediate enzymes of isoprenoid metabolism as anticancer targets. Wiemer AJ, Hohl RJ, Wiemer DF. Anticancer Agents Med Chem. 2009 Jun;9(5):526-42. PubMed

2008

Quantitative determination of farnesyl and geranylgeranyl diphosphate levels in mammalian tissue. Tong H, Wiemer AJ, Neighbors JD, Hohl RJ. Anal Biochem. 2008 Jul 15;378(2):138-43. PubMed

Pivaloyloxymethyl-modified isoprenoid bisphosphonates display enhanced inhibition of cellular geranylgeranylation. Wiemer AJ, Yu JS, Shull LW, Barney RJ, Wasko BM, Lamb KM, Hohl RJ, Wiemer DF. Bioorg Med Chem. 2008 Apr 1;16(7):3652-60. PubMed

Inhibition of geranylgeranyl diphosphate synthase induces apoptosis through multiple mechanisms and displays synergy with inhibition of other isoprenoid biosynthetic enzymes. Dudakovic A, Wiemer AJ, Lamb KM, Vonnahme LA, Dietz SE, Hohl RJ. J Pharmacol Exp Ther. 2008 Mar;324(3):1028-36. PubMed

Mono- and dialkyl isoprenoid bisphosphonates as geranylgeranyl diphosphate synthase inhibitors. Wiemer AJ, Yu JS, Lamb KM, Hohl RJ, Wiemer DF. Bioorg Med Chem. 2008 Jan 1;16(1):390-9. PubMed

2007

Synthesis of fluorescently tagged isoprenoid bisphosphonates that inhibit protein geranylgeranylation. Maalouf MA, Wiemer AJ, Kuder CH, Hohl RJ, Wiemer DF. Bioorg Med Chem. 2007 Mar 1;15(5):1959-66. PubMed

Total synthesis of (R,R,R)- and (S,S,S)-schweinfurthin F: differences of bioactivity in the enantiomeric series. Mente NR, Wiemer AJ, Neighbors JD, Beutler JA, Hohl RJ, Wiemer DF. Bioorg Med Chem Lett. 2007 Feb 15;17(4):911-5. PubMed

Digeranyl bisphosphonate inhibits geranylgeranyl pyrophosphate synthase. Wiemer AJ, Tong H, Swanson KM, Hohl RJ. Biochem Biophys Res Commun. 2007 Feb 23;353(4):921-5. PubMed

2006

Synthesis and biological activity of isoprenoid bisphosphonates. Shull LW, Wiemer AJ, Hohl RJ, Wiemer DF. Bioorg Med Chem. 2006 Jun 15;14(12):4130-6. PubMed

2004

Synthesis and activity of fluorescent isoprenoid pyrophosphate analogues. Kim M, Kleckley TS, Wiemer AJ, Holstein SA, Hohl RJ, Wiemer DF. J Org Chem. 2004 Nov 26;69(24):8186-93. PubMed

2002

Stereoselective synthesis of the 5′-hydroxy-5′-phosphonate derivatives of cytidine and cytosine arabinoside. Chen X, Wiemer AJ, Hohl RJ, Wiemer DF. J Org Chem. 2002 Dec 27;67(26):9331-9. PubMed

2000

Synthesis of phosphonate derivatives of uridine, cytidine, and cytosine arabinoside. Jung KY, Hohl RJ, Wiemer AJ, Wiemer DF. Bioorg Med Chem. 2000 Oct;8(10):2501-9. PubMed